Related Experiment Video
Updated: Jan 13, 2026

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
Published on: July 30, 2020
Finding an Achilles' heel of cancer cells: Exonized Alu elements in AURKA
Beatrice Zhang1, Omar Abdel-Wahab2
1Tri-Institutional Program in Computational Biology and Medicine, Weill Cornell Medicine, New York, NY, USA; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract:
In this issue of Molecular Cell, Kral et al.1 identify a targetable, novel mechanism of pancreatic ductal adenocarcinoma (PDAC) tumorigenesis via SRSF1 splicing-mediated regulation of an Alu-derived exon in Aurora kinase A (AURKA).
Insights
Researchers discovered a new mechanism driving pancreatic ductal adenocarcinoma (PDAC) through splicing factor SRSF1. This involves regulation of an Alu-derived exon in Aurora kinase A (AURKA), offering a potential therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Gene Regulation
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with limited therapeutic options.
- Aberrant gene expression and splicing are hallmarks of cancer development.
- Aurora kinase A (AURKA) is frequently overexpressed in PDAC and promotes tumorigenesis.
Purpose of the Study:
- To identify novel mechanisms driving PDAC tumorigenesis.
- To investigate the role of splicing factor SRSF1 in PDAC.
- To explore the regulation of AURKA by splicing in PDAC.
Main Methods:
- Analysis of patient-derived PDAC samples.
- Splicing assays to study exon inclusion.
- CRISPR-based screening to identify key splicing factors.
- Western blotting and immunohistochemistry to assess protein levels.
Main Results:
- SRSF1 directly regulates the inclusion of an Alu-derived exon in AURKA mRNA.
- This aberrant splicing event leads to increased AURKA protein levels in PDAC.
- SRSF1-mediated AURKA regulation is a critical driver of PDAC cell proliferation and survival.
- Targeting SRSF1 or the aberrant splicing event shows therapeutic potential in preclinical models.
Conclusions:
- SRSF1-mediated splicing of an Alu-derived exon in AURKA represents a novel mechanism of PDAC tumorigenesis.
- This pathway is a potential target for novel PDAC therapies.
- Further investigation into splicing-based therapeutic strategies for PDAC is warranted.
Related Concept Videos
Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
Nucleotide Excision Repair
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Base Excision Repair
The first step of...
DNA Damage can Stall the Cell Cycle

